Bibliography
- American Cancer Society. Cancer Facts and figures 2005 [on-line] Available from: URL: www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf
- Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-refractory prostate cancer. Cancer 1993;71:1098-109
- Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
- Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
- Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA. Potential antitumor agents. 61. Structure–activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthenone-4-acetic acids. J Med Chem 1991;34:217-20
- Ching L-M, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90:906-10
- Ching L-M, Cao Z, Kieda C, et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 2002;86:1937-42
- Zhao L, Ching L-M, Kestell P, et al. Mechanisms of tumor vascular shutdown induced by 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 2005;116:322-6
- Joseph WR, Cao Z, Mountjoy KG, et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999;59:633-8
- Mcphail LD, Chung Y-L, Madhu B, et al. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005;11:3705-13
- Woon S-T, Zwain S, Schooltink MA, et al. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Eur J Cancer 2003;39:1176-83
- Woon ST, Hung SSC, Wu DCF, et al. NF-kappa B-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res 2007;27:327-34
- Zhao L, Marshall ES, Kelland LR, Baguley BC. Evidence for the involvement of p38 MAP kinase in the action of the vascular disupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs 2007;25:271-6
- Wallace A, Larosa DF, Kapoor V, et al. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumour cytotoxic T lymphocytes. Cancer Res 2007;67:7011-19
- Roberts ZJ, Goutagny N, Perea P-Y, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signalling axis. J Exp Med 2007;204:1559-69
- Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8
- Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35
- Rustin GJS, Bradley C, Galbraith S, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase 1 clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-7
- Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a Phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50
- Jameson MB, Baguley BC, Kestell P, Zhao L, Paxton JW, Thompson PI. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel vascular disrupting agent, in a Phase I clinical trial. Cancer Chemother Pharmacol 2007;59:681-7
- Mckeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumors: a Phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84
- Galbraith SM, Rustin GJS, Lodge MA, et al. Effects of 5,6-Dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast enhanced magnetic resonance imaging. J Clin Oncol 2002;20(18):3826-40
- Siim BG, Lee AE, Shalal-zwain S, Pruijn FB, Mckeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;15:43-52
- Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Cur Cancer Ther Rev 2005;1:1-9
- Mckeage MJ, Kelland LR. 5,6-dimethylxanthenoine-4-acetic acid (DMXAA) clinical potential in combination with taxane-based chemotherapy. Am J Cancer 2006;5(3):155-62
- Pruijn FB, Vandaalen M, Holford NHG, et al. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39(6):541-6
- Clarke SJ, Rivory L. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114
- Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmaology and therapeutic potential. Drugs 1998;55:5-30
- Rosenthal M, Pili R. Randomised Phase II study in prostate cancer with or owthout DMXAA (AS1404) in hormone refractory metastatic prostate cancer (HRMPC). Proceedings of the American Society for Clinical Oncology, 2007:Abstract 219
- Mckeage M. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Proceedings of the American Society for Clinical Oncology, 2006:Abstract 7102
- Mckeage MJ, von Pawel J. Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer. Proceedings of the World Congress on Lung Cancer, 2007:Abstract P3-116